CapsoVision raises $18M from existing shareholders in direct offering
What's the deal? CapsoVision, a Nasdaq-listed medical technology company, has raised $18 million through a registered direct stock offering to existing shareholders. On September 17, 2026, it agreed to sell 3,163,444 shares of common stock at $5.69 each — a roughly 5% discount to the prior Nasdaq close. The offer, conducted without an underwriter, was expected to close around September 18, 2026.
Who's backing it? Existing shareholders Star One Global Capital LimitedDealroom has a profile for this one. Try Dealroom → and Eliyahou Harari are providing the full funding. The company's board approved the deal, and its audit committee reviewed it.
What's the endgame? CapsoVision develops capsule endoscopy products — minimally invasive diagnostic imaging aimed at improving gastrointestinal diagnostics. It plans to use the capital for general corporate purposes, including sales and marketing, research and development, and working capital.
What could go wrong? The company carries weak financials, with large losses and significant cash burn despite strong revenue growth and healthy gross margins, according to TipRanks' AI analyst Spark, which rates the stock Neutral. The offering also modestly dilutes existing ownership. CapsoVision currently holds a market cap of $299.8 million.
The signal: Raising capital directly from insiders rather than through a public underwritten offering is a low-friction way for a small-cap medical device maker to shore up its balance sheet — a sign of continued backer confidence, even as the company works toward upcoming regulatory milestones and improving second-half revenue.
Read more: tipranks.com
Image credit: Generated with Gemini
